Intellia Therapeutics NTLA Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $66.09M+45.0% | $67.67M+16.9% | $57.53M+27.8% | $52.86M+10.4% | $45.57M-16.4% | ||
| $361.17M-22.0% | $388.86M-16.6% | $417.09M-9.0% | $445.72M-0.7% | $462.89M+2.9% | ||
| $125.64M+1.5% | $119.8M-4.8% | $119.17M-2.6% | $119.16M-1.8% | $123.75M+3.0% | ||
| $486.81M-17.0% | $508.66M-14.1% | $536.26M-7.7% | $564.88M-0.9% | $586.64M+2.9% | ||
| -$420.72M+22.2% | -$440.99M+17.5% | -$478.73M+11.0% | -$512.02M+2.3% | -$541.07M-4.6% | ||
| -636.6%+551pp | -651.7%+271pp | -832.2%+363pp | -968.7%+126pp | -1,187.4%-238pp | ||
| $26.12M+72.4% | $28.3M+85.6% | $32.92M+113% | $31.83M+109% | $15.15M-52.4% | ||
| -$394.6M+25.0% | -$412.69M+20.5% | -$445.81M+14.6% | -$480.19M+5.6% | -$525.91M-8.3% | ||
| -597%+557pp | -609.9%+287pp | -774.9%+386pp | -908.5%+154pp | -1,154.1%-264pp | ||
| -$3.53+32.4% | -$3.82+27.1% | -$4.26+21.7% | -$4.68+14.6% | -$5.22+2.6% | ||
| -$411.23M+22.5% | -$431.21M+17.7% | -$468.76M+11.1% | -$501.86M+2.4% | -$530.8M-4.5% | ||
| -622.2%+543pp | -637.2%+268pp | -814.8%+357pp | -949.5%+124pp | -1,164.8%-233pp | ||
| -$420.72M+22.2% | -$440.99M+17.5% | -$478.73M+11.0% | -$512.02M+2.3% | -$541.07M-4.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Intellia Therapeutics's income statement data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.